Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HV-101 TIL therapy in advanced solid tumors
NCT05868915Phase 1Terminated
- Sponsor
- Hervor Therapeutics
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocyte cells in solid tumor (advanced stage), sponsored by Hervor Therapeutics. Primary endpoint: Safety of HV-101 at 730 days. Started Aug 2023; status: terminated.
02
Drugs
autologous tumor-infiltrating lymphocyte cells
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05868915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05868915.